capecitabine actavis
actavis group ptc ehf - kapecitabinas - plėvele dengtos tabletės - 150 mg; 500 mg - capecitabine
capecitabine fresenius kabi
fresenius kabi oncology plc - kapecitabinas - plėvele dengtos tabletės - 500 mg; 150 mg - capecitabine
capecitabine norameda
norameda, uab - kapecitabinas - plėvele dengtos tabletės - 150 mg; 500 mg - capecitabine
capecitabine sandoz
sandoz d.d. - kapecitabinas - plėvele dengtos tabletės - 500 mg; 150 mg - capecitabine
capecitabine zentiva
zentiva k.s. - kapecitabinas - plėvele dengtos tabletės - 150 mg; 500 mg - capecitabine
fluorouracil accord
accord healthcare b.v. - fluorouracilas - injekcinis ar infuzinis tirpalas - 50 mg/ml - fluorouracil
nerlynx
pierre fabre medicament - neratinib - krūties navikai - antinavikiniai vaistai - nerlynx yra nurodyta pratęstas oksaliplatina suaugusių pacientų su anksti hormonų receptorių, her2 teigiamą-overexpressed/papildyta, krūties vėžio ir kurie yra mažiau kaip vienus metus nuo užbaigti iki palaikomosios trastuzumab pagrįstas terapija.
sorafenib teva
teva b.v. - sorafenibas - plėvele dengtos tabletės - 200 mg - sorafenib
sorafenib sandoz
sandoz d.d. - sorafenibas - plėvele dengtos tabletės - 200 mg - sorafenib
aybintio
samsung bioepis nl b.v. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).